

Our ref: IG/FOI/FOI.145.26

20 April 2026

Sent via email to: [REDACTED]

Dear [REDACTED]

## Request under the Freedom of Information Act 2000

I write further to your request for information, which was received on 1 April 2026, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) partly holds the information that you require. For ease of reference your request is set out below and the Health Board's response follows each question individually.

### Your Freedom of Information (FOI) Request and Powys Response (Bold):

Under the Freedom of Information Act 2000, I would like to request the following information regarding the use of injectable pharmacological treatments for overweight and obesity (e.g. GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists). For the period from 1 September 2024 to 1 April 2026:

Q1a. Are injectable pharmacological treatments for overweight and obesity currently being initiated for patients as part of routine services commissioned or delivered by your organisation? – **Yes.**

Q1b. If so, please identify which medication(s) are currently used as first-line injectable pharmacological therapy for overweight and obesity within commissioned services – **Mounjaro and Saxenda.**

Q2a. What are the eligibility criteria for patients to access injectable pharmacological treatments for overweight and obesity within your organisation? – **Prioritisation using the position statement from the Society for Endocrinology and Obesity Management Collaborative UK and at least 12 weeks of demonstrated behaviour-change engagement as recommended in the NICE guidance.**

Q2b. Where these criteria are already published online, please provide the relevant link and confirm whether the published criteria are currently being

applied in practice – **Please see the links below. I can confirm that the published criteria are currently being applied in practice.**

- [A Joint Position Statement by the Society for Endocrinology and Obesity Management Collaborative UK](#)
- [NICE Guidance: Overweight and Obesity Management](#)

Q3. Please confirm whether the model of care through which these treatments are (or will be) delivered:

- Directly from general practice
- Primary care-led weight management service (e.g. GP or pharmacist-led weight management service, community weight management hub, etc.)
- **Tier 3 specialist weight management services only**
- Other (please specify).

Q4. Please confirm whether the relevant pathway within your organisation is currently:

- **operational and accepting referrals**
- operational but limited (e.g. pilot sites)
- approved but not yet implemented
- currently under development.

Q5. Please provide copies of any key or current clinical pathways, service specifications, prescribing guidance, or referral criteria relating to the use of injectable pharmacological treatments for overweight and obesity, if held.

**This information is not available.**

If you are dissatisfied with the handling or response to your request, you have the right to ask for an internal review. Should you wish an internal review, please quote the reference number and send your correspondence to the above address.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at:

Address: Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH.

Telephone: 0330 414 6421

Complaints Portal: [www.ico.org.uk/foicomplaints](http://www.ico.org.uk/foicomplaints)

Web site: <https://ico.org.uk/>

### **Re-use of Public Sector Information**


All information supplied by the Health Board in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2015.

Under the terms of the Regulations, the Health Board will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be

free; however, the Health Board reserves the right, in certain circumstances to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information including a sample license terms and fees can be found at [Open Government Licence](#).

Yours sincerely



**Elaine Lorton**  
**Executive Director of Primary Community Care and Mental Health**

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.